The utility of the PFA-100 in the identification of von Willebrand disease: A concise review

Seminars in Thrombosis and Hemostasis

Volumn 32, Issue 5, 2006, Pages 537-545

  Favaloro, Emmanuel J ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

Bleeding disorders; Diagnosis; Laboratory assessment; PFA 100; Platelet function; Review; Von Willebrand disease; Von Willebrand disorder (vWD); Von Willebrand Factor (vWF)

Indexed keywords

ACETYLSALICYLIC ACID; DESMOPRESSIN;

ANALYZER; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; HEMATOCRIT; HEMOSTASIS; HUMAN; LABORATORY DIAGNOSIS; MONITORING; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; THROMBOCYTE DYSFUNCTION; VON WILLEBRAND DISEASE;

AUTOMATION; DRUG MONITORING; HUMANS; PLATELET FUNCTION TESTS; VON WILLEBRAND DISEASE;

EID: 33746650150     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-947869     Document Type: Review

References (41)

1. Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in-vitro platelet function analyser: PFA-100®. Semin Thromb Hemost 1995;21(suppl 2): 106-112
2. Mammen EF, Alshameeri RS, Comp PC. Preliminary data from a field trial of the PFA-100® system. Semin Thromb Hemost 1995;21(suppl 2):113-120
3. Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000;111:733-744
4. Favaloro EJ. Utility of the PFA-100® for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations. Haemophilia 2001;7:170-179
5. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001;138:152-163
6. Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol 2005;130:3-10
7. Favaloro EJ. Clinical utility of the PFA-100®. Curr Opin Hematol 2002;9:407-415
8. Favaloro EJ. Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand's disease. Blood Rev 1999;13:185-204
9. Favaloro EJ. Appropriate laboratory assessment as a critical facet in the proper diagnosis and classification of von Willebrand disorder. Best Pract Res Clin Haematol 2001;14:299-319
10. Favaloro EJ. Laboratory identification of von Willebrand Disease: technical and scientific perspectives. Semin Thromb Hemost 2006;32:456-471
11. Dalby MC, Davidson SJ, Burman JF, Davies SW. Diurnal variation in platelet aggregation with the PFA-100 platelet function analyser. Platelets 2000;11:320-324
12. Feuring M, Christ M, Roell A, et al. Alterations in platelet function during the ovarian cycle. Blood Coagul Fibrinolysis 2002;13:443-447
13. Lippi G, Franchini M, Brocco G, Manzato F. Influence of the ABO blood type on the platelet function analyzer PFA-100. Thromb Haemost 2001;85:369-370
14. Moeller A, Weippert-Kretschmer M, Prinz H, Kretschmer V. Influence of ABO blood groups on primary hemostasis. Transfusion 2001;41:56-60
15. Nitu-Whalley IC, Lee CA, Brown SA, Riddell A, Hermans C. The role of the platelet function analyser (PFA-100) in the characterization of patients with von Willebrand's disease and its relationships with von Willebrand factor and the ABO blood group. Haemophilia 2003;9:298-302
16. Carcao MD, Blanchette VS, Dean JA, et al. The Platelet Function Analyzer (PFA-100): a novel in-vitro system for evaluation of primary haemostasis in children. Br J Haematol 1998;101:70-73
17. Dean JA, Blanchette VS, Carcao MD, et al. von Willebrand Disease in a paediatric-based population-comparison of type 1 diagnostic criteria and use of the PFA-100® and a von Willebrand factor/collagen-binding assay. Thromb Haemost 2000;84:401-409
18. Fressinaud E, Veyradier A, Truchaud F, et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998;91:1325-1331
19. Fressinaud E, Veyradier A, Sigaud M, Boyer-Neumann C, Le Boterff C, Meyer D. Therapeutic monitoring of von Willebrand disease: interest and limits of a platelet function analyser at high shear rates. Br J Haematol 1999;106:777-783
20. Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24:195-202
21. Cattaneo M, Federici AB, Lecchi A, et al. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999;82:35-39
22. Favaloro EJ, Facey D, Henniker A. Use of a novel platelet function analyzer (PFA-100) with high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand's disease and other disorders. Am J Hematol 1999;62:165-174
23. Favaloro EJ, Kershaw G, Bukuya M, Hertzberg M, Koutts J. Laboratory diagnosis of von Willebrand disorder (VWD) and monitoring of DDAVP therapy, efficacy of the PFA-100® and VWF:CBA as combined diagnostic strategies. Haemophilia 2001;7:180-189
24. Favaloro EJ. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study of 148 patients-a rebuttal. J Thromb Haemost 2004;2:2280-2282
25. Harrison P, Robinson MS, Mackie IJ, et al. Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis. Blood Coagul Fibrinolysis 1999; 10:25-31
26. Harrison P, Robinson M, Liesner R, et al. The PFA-100: a potential rapid screening tool for the assessment of platelet dysfunction. Clin Lab Haematol 2002;24:225-232
27. Kerenyi A, Schlammadinger A, Ajzner E, et al. Comparison of PFA-100 closure time and template bleeding time of patients with inherited disorders causing defective platelet function. Thromb Res 1999;96:487-492
28. Schlammadinger A, Kerenyi A, Muszbek L, Boda Z. Comparison of the O'Brien filter test and the PFA-100 platelet analyser in the laboratory diagnosis of von Willebrand's disease. Thromb Haemost 2000;84:88-92
29. Meskal A, Vertessen F, Van der Planken M, Berneman ZN. The platelet function analyzer (PFA-100) may not be suitable for monitoring the therapeutic efficiency of von Willebrand concentrate in type III von Willebrand disease. Ann Hematol 1999;78:426-430
30. Ortel TL, James AH, Thames EH, Moore KD, Greenberg CS. Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center. Thromb Haemost 2000;84:93-97
31. Buyukasik Y, Karakus S, Goker H, et al. Rational use of the PFA-100 device for screening of platelet function disorders and von Willebrand disease. Blood Coagul Fibrinolysis 2002; 13:349-353
32. Wuillemin WA, Gasser KM, Zeerleder SS, Lammle B. Evaluation of a Platelet Function Analyser (PFA-100) in patients with a bleeding tendency. Swiss Med Wkly 2002; 132:443-448
33. Cariappa R, Wilhite TR, Parvin CA, Luchtman-Jones L. Comparison of PFA-100 and bleeding time testing in pediatric patients with suspected hemorrhagic problems. J Pediatr Hematol Oncol 2003;25:474-479
34. Posan E, McBane RD, Grill DE, Motsko CL, Nichols WL. Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice. Thromb Haemost 2003;90:483-490
35. Quiroga T, Goycoolea M, Munoz B, et al. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients. J Thromb Haemost 2004;2: 892-898
36. Favaloro EJ, Soltani S, McDonald J, Grezchnik E, Easton L, Favaloro JWC. Reassessment of ABO-blood group, gender and age on laboratory parameters used to diagnose von Willebrand Disorder (VWD): potential influence on the diagnosis versus the potential association with risk of thrombosis. Am J Clin Pathol 2005;124:910-917
37. Franchini M, Gandini G, Manzato F, Lippi G. Evaluation of the PFA-100 system for monitoring desmopressin therapy in patients with type 1 von Willebrand's disease. Haematologica 2002;87:670
38. Francis JL, Francis D, Larson L, Helms E, Garcia M. Can the platelet function analyser (PFA)-100 test substitute for the template bleeding time in routine clinical practice. Platelets 1999;10:132-136
39. Favaloro EJ. von Willebrand factor (VWF) collagen binding (activity) assay (VWF:CBA) in the diagnosis of von Willebrand's disorder (VWD): a 15-year journey. Semin Thromb Hemost 2002;28:191-202
40. Haubelt H, Anders C, Vogt A, Hoerdt P, Seyfert UT, Hellstern P. Variables influencing Platelet Function Analyzer-100 closure times in healthy individuals. Br J Haematol 2005;130:759-767
41. Cattaneo M. Are the bleeding time and PFA-100 useful in the initial screening of patients with mucocutaneous bleedings of hereditary nature? J Thromb Haemost 2004;2:890-891